Special Update on Cellceutix
by DrKSSMDPhD | September 3, 2014 11:35 pm
This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.
Source URL: https://www.stockgumshoe.com/2014/09/microblog-special-update-on-cellceutix/
Thought for $ACHN
http://seekingalpha.com/article/2479545-achillion-an-options-strategy-for-a-potential-acquisition
justirregular,
I couldn’t let your mention of Junior Watson go without me listing another “Junior” guitarist, the “one-and-only” Junior Brown: http://www.youtube.com/watch?v=497ZmAsGAT4
Worth a read. The pot debate is being skewed by opioid makers
https://news.vice.com/article/leading-anti-marijuana-academics-are-paid-by-painkiller-drug-companies?utm_source=vicenewstwitter
Reminds of stories that refrigerant makers funded ozone hole/Freon banners when patents ran out on Freon and new types priced 10 times higher . I have no way of knowing if that was true or not,but ozone thinning,,,not a hole,, appears every antarctic winter in area of the sky in shadow of the earth,,,, probably just as it has always done. Ozone is formed by high intensity ultraviolet light striking outer atmosphere and dissipates when light is cut off.
Dr.KSS: Two new Bio IPOs are coming up today and tomorrow — Revo Biologics and PROQR Therapeutics. Any info on these?
Hi Mr. Paglee, let me look into those this evening after I wrap up a few things. Mind if I post about them over on the new thread, the one about pain and opioids?
Re your posting this morning under Comment #7 above: Thanks for the excellent 10K summary, Patrick. I would add that the patent litigation settlement agreement recently executed between Cellceutix, Menon, and Aruda includes the following provision that restricts the issuance and exercise of stock options for the next 3 years:
“Cellceutix warrants that
(b) except for (i) the exercise of stock options granted before 1 January 2014 for a strike price that at the time was fair market value, and (ii) issuance to Mr. Leo Ehrlich of stock on conversion of a convertible loan dated before 1 January 2014, it will not issue stock to its officers or directors or their respective family members, or to its Affiliates for less than fair market value and will not issue stock options or other equity-oriented rights to its officers or directors or their respective family members or Affiliates for a purchase price or strike price that is less than fair market value, in either case for a period of three years following the Effective Date”
On its face, this provision provides limited protection to minority shareholders, In the post-litigation settlement context, however, it appears highly probable that Menon’s management actions and personal conduct vis-vis the Corporation and its minority shareholders will toe the mark – if for no other reasons than: (1) he knows that his decisions and actions will henceforth be subjected to increased scrutiny; and (2) he undoubtedly want to avoid the pain and suffering that attends the defense of high stake litigation, as well as SEC enforcement action. Additionally, it seems unlikely that Menon and Ehrlich would engage in self-serving conduct that may jeopardize uplisting to the NYSE or NASDAQ. Long CTIX.
PS. Although logic would favor posting your CTIX comment on this thread, custom and practice over the past several months indicates that most irregulars would prefer posting of ongoing biotech-investment-related comments on the most current KSS thread. Thanks again.
http://seekingalpha.com/pr/11081145-cellceutix-to-president-obama-we-have-the-tools-and-will-rise-up-to-the-challenge-to-prevent-antibiotic-resistant-bacteria-becoming-a-serious-threat-to-public-health.
DR KSS, Thanks for a great article. If you have time could you take a quick look at AEMD. It goes beyond scrubbing blood cells to “clean” them up, to actually cleaning out certain bad stuff. (They mentioned a possible help for EBOLA). I defer to your superior skills to see if it is possible. P.S. If the board has a boca botox buffoon on it there is no need for a reply. I’m still laughing every time I think about it.
To Timothy Ludolph and others: Aethlon Medical $AEMD is a San Diego firm that ideologically seems to be spawned from $CTSO and $CERS. $CERS is a brilliant company with a method for inactivating all DNA and RNA in blood, but is permanently stalled on getting US approval (though its method is in near-global use to treat blood products before transfusion). $CTSO, as I have explained many times in these threads, is highly deceptive junk science that not only does not help people (faulty theory, multiple cases of failed trials) but also harms them.
$AEMD came up some months back. It may sometimes seem that I am a grouch who swats at every mentioned company and by implication the people who bring them up. I don’t make such comments in anger, but feel it is vital to call deceptive, junk biotech by what it is. AEMD is total garbage. It has never done a clinical trial, and the one scheduled to start in November of “purifying” away HCV virions from blood of end-stage kidney disease is total crap. In lab systems, they have seen at most a 50 per cent reduction in virus (far too little to matter) and anyway, this will in no way ever find use. Renal patients can’t get ribavirin, but they are easily cured by HCV drugs like those of Gilead.
AEMD is attempting open deceit of retail investors who don’t have scientific expertise. Few seem to notice it has been around since 1998, has not accomplished ANYTHING and trades at inexorably ever-lower prices. A few may get duped. Don’t be one.